dc.contributor.author | Nauck, Michael A. | |
dc.contributor.author | McGuire, Darren K. | |
dc.contributor.author | Pieper, Karen S. | |
dc.contributor.author | Lokhnygina, Yuliya | |
dc.contributor.author | Strandberg, Timo E. | |
dc.contributor.author | Riefflin, Axel | |
dc.contributor.author | Delibasi, Tuncay | |
dc.contributor.author | Peterson, Eric D. | |
dc.contributor.author | White, Harvey D. | |
dc.contributor.author | Scott, Russell | |
dc.contributor.author | Holman, Rury R. | |
dc.date.accessioned | 2021-06-03T05:31:05Z | |
dc.date.available | 2021-06-03T05:31:05Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1475-2840 | |
dc.identifier.uri | http://dx.doi.org/10.1186/s12933-019-0921-2 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719352/ | |
dc.identifier.uri | http://hdl.handle.net/11655/24080 | |
dc.description.abstract | Background To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Methods TECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to sitagliptin or placebo, in addition to usual care. For those who had a within-trial MI, we analyzed case fatality, and for those with a nonfatal MI, we examined a composite cardiovascular (CV) outcome (CV death or hospitalization for heart failure [hHF]) by treatment group, using Cox proportional hazards models left-censored at the time of the first within-trial MI, without and with adjustment for potential confounders, in intention-to-treat analyses. Results During TECOS, 616 participants had ≥ 1 MI (sitagliptin group 300, placebo group 316, HR 0.95, 95% CI 0.81–1.11, P = 0.49), of which 25 were fatal [11 and 14, respectively]). Of the 591 patients with a nonfatal MI, 87 (15%) died subsequently, with 66 (11%) being CV deaths, and 57 (10%) experiencing hHF. The composite outcome occurred in 58 (20.1%; 13.9 per 100 person-years) sitagliptin group participants and 50 (16.6%; 11.7 per 100 person-years) placebo group participants (HR 1.21, 95% CI 0.83–1.77, P = 0.32, adjusted HR 1.23, 95% CI 0.83–1.82, P = 0.31). On-treatment sensitivity analyses also showed no significant between-group differences in post-MI outcomes. Conclusions In patients with type 2 diabetes and ASCVD experiencing an MI, sitagliptin did not reduce subsequent risk of CV death or hHF, contrary to expectations derived from preclinical animal models., Trial registration clinicaltrials.gov no. NCT00790205 | |
dc.language.iso | en | |
dc.relation.isversionof | 10.1186/s12933-019-0921-2 | |
dc.rights | Attribution 4.0 United States | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Sitagliptin Does Not Reduce The Risk Of Cardiovascular Death Or Hospitalization For Heart Failure Following Myocardial Infarction In Patients With Diabetes: Observations From Tecos | |
dc.title.alternative | Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Cardiovascular Diabetology | |
dc.contributor.department | Kardiyoloji | |
dc.identifier.volume | 18 | |
dc.description.index | PubMed | |
dc.description.index | WoS | |
dc.description.index | Scopus | |